Clinical Trial Update: A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

This update summarizes a Phase 2 study of oral erdafitinib in patients with recurrent non-muscle invasive bladder cancer, including FGFR3-mutant tumors, which i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, Recurrent Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING